Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2026-03-16 9:56 pm Purchase | 2026-03-13 | 13D | Eupraxia Pharmaceuticals Inc. EPRX | Joseph S. Freedman | 5,843,215 9.000% | 310,000 (+5.60%) | Filing History |
| 2026-02-17 11:09 am Sale | 2025-12-31 | 13G | Eupraxia Pharmaceuticals Inc. EPRX | MANCHESTER MANAGEMENT CO LLC | 4,904,523 9.200% | -935,034 (-16.01%) | Filing History |
| 2025-11-14 4:37 pm Purchase | 2025-09-30 | 13G | Eupraxia Pharmaceuticals Inc. EPRX | DISBROW ROBERT | 3,568,150 7.000% | 3,568,150 (New Position) | Filing History |
| 2025-11-14 09:10 am Purchase | 2025-09-30 | 13G | Eupraxia Pharmaceuticals Inc. EPRX | Beutel Goodman & Co Ltd. | 4,058,899 8.000% | 4,058,899 (New Position) | Filing History |
| 2025-11-13 12:14 pm Purchase | 2024-12-31 | 13G | Eupraxia Pharmaceuticals Inc. EPRX | MANCHESTER MANAGEMENT CO LLC | 5,839,557 10.900% | 5,839,557 (New Position) | Filing History |
| 2025-09-26 9:19 pm Purchase | 2025-09-24 | 13D | Eupraxia Pharmaceuticals Inc. EPRX | Joseph S. Freedman | 5,533,215 10.200% | 5,533,215 (New Position) | Filing History |
| 2024-11-14 4:17 pm Unchanged | 2024-11-14 | 13G | Eupraxia Pharmaceuticals Inc. EPRX | DISBROW ROBERT | 0 0.000% | 0 (Unchanged) | Filing |
| 2024-11-07 4:10 pm Unchanged | 2024-11-07 | 13D | Eupraxia Pharmaceuticals Inc. EPRX | Joseph S. Freedman | 0 0.000% | 0 (Unchanged) | Filing |